Your browser doesn't support javascript.
loading
Fucoidan-based dual-targeting mesoporous polydopamine for enhanced MRI-guided chemo-photothermal therapy of HCC via P-selectin-mediated drug delivery.
Shu, Gaofeng; Shen, Lin; Ding, Jiayi; Yu, Junchao; Chen, Xiaoxiao; Guo, Xiaoju; Qiao, Enqi; Chen, Yaning; Lu, Chenying; Zhao, Zhongwei; Du, Yongzhong; Chen, Minjiang; Ji, Jiansong.
Afiliação
  • Shu G; Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Institute of Imaging Diagnosis and Minimally Invasive Intervention Research, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
  • Shen L; Department of radiology, Lishui Hospital of Zhejiang University, School of Medicine, Lishui 323000, China.
  • Ding J; Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Institute of Imaging Diagnosis and Minimally Invasive Intervention Research, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
  • Yu J; Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Institute of Imaging Diagnosis and Minimally Invasive Intervention Research, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
  • Chen X; Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Institute of Imaging Diagnosis and Minimally Invasive Intervention Research, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
  • Guo X; Department of radiology, Lishui Hospital of Zhejiang University, School of Medicine, Lishui 323000, China.
  • Qiao E; Shaoxing University School of Medcine, Shaoxing 312000, China.
  • Chen Y; Department of radiology, Lishui Hospital of Zhejiang University, School of Medicine, Lishui 323000, China.
  • Lu C; Department of radiology, Lishui Hospital of Zhejiang University, School of Medicine, Lishui 323000, China.
  • Zhao Z; Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Institute of Imaging Diagnosis and Minimally Invasive Intervention Research, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
  • Du Y; Department of radiology, Lishui Hospital of Zhejiang University, School of Medicine, Lishui 323000, China.
  • Chen M; Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Institute of Imaging Diagnosis and Minimally Invasive Intervention Research, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
  • Ji J; Department of radiology, Lishui Hospital of Zhejiang University, School of Medicine, Lishui 323000, China.
Asian J Pharm Sci ; 17(6): 908-923, 2022 Nov.
Article em En | MEDLINE | ID: mdl-36600896
ABSTRACT
The development of novel theranostic agents with outstanding diagnostic and therapeutic performances is still strongly desired in the treatment of hepatocellular carcinoma (HCC). Here, a fucoidan-modified mesoporous polydopamine nanoparticle dual-loaded with gadolinium iron and doxorubicin (FMPDA/Gd3+/DOX) was prepared as an effective theranostic agent for magnetic resonance imaging (MRI)-guided chemo-photothermal therapy of HCC. It was found that FMPDA/Gd3+/DOX had a high photothermal conversion efficiency of 33.4% and excellent T1-MRI performance with a longitudinal relaxivity (r1) value of 14.966 mM-1·s - 1. Moreover, the results suggested that FMPDA/Gd3+/DOX could effectively accumulate into the tumor foci by dual-targeting the tumor-infiltrated platelets and HCC cells, which resulted from the specific interaction between fucoidan and overexpressed p-selectin receptors. The excellent tumor-homing ability and MRI-guided chemo-photothermal therapy therefore endowed FMPDA/Gd3+/DOX with a strongest ability to inhibit tumor growth than the respective single treatment modality. Overall, our study demonstrated that FMPDA/Gd3+/DOX could be applied as a potential nanoplatform for safe and effective cancer theranostics.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Asian J Pharm Sci Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Asian J Pharm Sci Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China